Clovis Oncology
CLVS
$0.08120
Share price
0.00%
Change (1 day)
-95.08%
Change (1 year)
Categories
P/S ratio for Clovis Oncology (CLVS)
P/S ratio as of April 2024 (TTM): 0.0885
According to Clovis Oncology's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 0.0884849. At the end of 2022 the company had a P/S ratio of 1.29.
P/S ratio history for Clovis Oncology from 2011 to 2022
PS ratio at the end of each year
| Year | P/S ratio | Change |
|---|---|---|
| 2022 | 1.29 | -45.05% |
| 2021 | 2.35 | -22.26% |
| 2020 | 3.03 | -24.48% |
| 2019 | 4.01 | -59.7% |
| 2018 | 9.94 | -83.88% |
| 2017 | 61.7 | -99.72% |
| 2016 | > 1000 | |
| 2015 | N/A | -100% |
| 2014 | 140 | |
| 2013 | N/A | |
| 2012 | N/A | |
| 2011 | N/A |
P/S ratio for similar companies or competitors
| Company | P/S ratio | P/S ratio differencediff. | Country |
|---|---|---|---|
 Johnson & Johnson JNJ | 3.79 | 4,178.21% | 🇺🇸 USA |
 Pfizer PFE | 2.46 | 2,677.60% | 🇺🇸 USA |
 AbbVie ABBV | 5.20 | 5,780.40% | 🇺🇸 USA |
 Eli Lilly LLY | 20.4 | 22,966.42% | 🇺🇸 USA |
 AstraZeneca AZN | 5.09 | 5,649.49% | 🇬🇧 UK |
 BioMarin Pharmaceutical BMRN | 6.36 | 7,083.18% | 🇺🇸 USA |